NDC 70114-440
CIMERLI
Ranibizumab-eqrn
CIMERLI is a Intravitreal Injection, Solution in the Human Prescription Drug category. It is labeled and distributed by Coherus Biosciences Inc. The primary component is Ranibizumab.
| Product ID | 70114-440_557e9461-76e9-4d5a-a165-b11af0979d39 |
| NDC | 70114-440 |
| Product Type | Human Prescription Drug |
| Proprietary Name | CIMERLI |
| Generic Name | Ranibizumab-eqrn |
| Dosage Form | Injection, Solution |
| Route of Administration | INTRAVITREAL |
| Marketing Start Date | 2022-10-03 |
| Marketing Category | BLA / |
| Application Number | BLA761165 |
| Labeler Name | Coherus BioSciences Inc |
| Substance Name | RANIBIZUMAB |
| Active Ingredient Strength | 0 mg/.05mL |
| Pharm Classes | Vascular Endothelial Growth Factor Inhibitor [EPC], Vascular Endothelial Growth Factor Inhibitors [MoA] |
| NDC Exclude Flag | N |
| Listing Certified Through | 2023-12-31 |
Packaging
NDC 70114-440-01
1 VIAL, SINGLE-DOSE in 1 CARTON (70114-440-01) > .05 mL in 1 VIAL, SINGLE-DOSE
| Marketing Start Date | 2022-10-03 |
| NDC Exclude Flag | N |
| Sample Package? | N |
Drug Details
NDC Crossover Matching brand name "CIMERLI" or generic name "Ranibizumab-eqrn"
| NDC | Brand Name | Generic Name |
|---|---|---|
| 70114-440 | CIMERLI | ranibizumab-eqrn |
| 70114-441 | CIMERLI | ranibizumab-eqrn |
Trademark Results [CIMERLI]
Mark Image Registration | Serial | Company Trademark Application Date |
|---|---|
 CIMERLI 90248177 not registered Live/Pending |
Coherus BioSciences, Inc. 2020-10-12 |
© 2025 FDA.report
This site is not affiliated with or endorsed by the FDA.